Activation of AMPK seems to precede mTORC1 and mTORC2 inhibition, restoration of GSK3β activity, β-catenin down-regulation and the impairment of CML cell proliferation. Here, GSK3B is linked to chronic myelogenous leukemia, BCR-ABL1 positive.